Cargando…

Combination of GT90001 and nivolumab in patients with advanced hepatocellular carcinoma: a multicenter, single-arm, phase 1b/2 study

BACKGROUND: GT90001 (also known as PF-03446962) is an anti-ALK-1 monoclonal antibody and has shown activity in hepatocellular carcinoma (HCC). This phase 1b/2 study was designed to determine the recommended phase 2 dose (RP2D) of GT90001 plus nivolumab, and assess the safety and anti-tumor activity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Chiun, Chang, Yi-Fang, Yen, Chia-Jui, Xu, Yu-Wei, Dong, Min, Tong, You-Zhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588186/ https://www.ncbi.nlm.nih.gov/pubmed/37858184 http://dx.doi.org/10.1186/s12916-023-03098-w

Ejemplares similares

Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open‐Label, Phase Ib Study
por: Lin, Chia‐Chi, et al.
Publicado: (2020)

Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
por: Martin-Broto, Javier, et al.
Publicado: (2020)

Low-dose nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2022)

Safety, Pharmacokinetics, and Pharmacodynamics of CC‐90001 (BMS‐986360), a c‐Jun N‐terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants
por: Ye, Ying, et al.
Publicado: (2022)

CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial
por: Popmihajlov, Zoran, et al.
Publicado: (2022)

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2023)

Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma
por: Lee, Jan-Mou, et al.
Publicado: (2022)

A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer
por: Hasegawa, Hirotaka, et al.
Publicado: (2022)

Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study
por: de la Torre-Aláez, Manuel, et al.
Publicado: (2022)

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
por: Wu, Wen-Chi, et al.
Publicado: (2022)

Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma
por: Yen, Tsai-Hung, et al.
Publicado: (2020)

Correction: Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study
Publicado: (2023)

Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases
por: Wong, Philip, et al.
Publicado: (2023)

Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study
por: Roessler, Daniel, et al.
Publicado: (2022)

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial
por: Yau, Thomas, et al.
Publicado: (2020)

Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma
por: Fujimura, Taku, et al.
Publicado: (2017)

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
por: Fessas, Petros, et al.
Publicado: (2020)

Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study
por: Kanda, S., et al.
Publicado: (2016)

Age-dependent development of liver fibrosis in Glmp(gt/gt) mice
por: Nesset, Cecilie K., et al.
Publicado: (2016)

Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Li, Yan, et al.
Publicado: (2022)

Multicentre, phase II study of gemcitabine and S‐1 in patients with advanced biliary tract cancer: TG1308 study
por: Chiang, Nai‐Jung, et al.
Publicado: (2020)

Search for the Higgs boson in the H ->WW->lvlv channel in ATLAS
por: Armbruster, A
Publicado: (2011)

Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma
por: Feng, Duan, et al.
Publicado: (2017)

Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date
por: Tella, Sri Harsha, et al.
Publicado: (2019)

Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure
por: Kim, Jaewoong, et al.
Publicado: (2020)

Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
por: Hsu, Chih-Hung, et al.
Publicado: (2014)

Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors
por: Zibelman, Matthew, et al.
Publicado: (2023)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

H->tau tau and H->tau nu with the ATLAS Detector at the LHC
por: Goncalo, R
Publicado: (2011)

Study of H(SUSY) -> Tautau -> l + Tau Jet + Etmis in CMS
por: Kinnunen, Ritva, et al.
Publicado: (1997)

Solar origin of Major GMSs with (-50nT>Dst>-100nT)
por: Kaur, S
Publicado: (2005)

Net widens for funding of <i>arXiv</i>
Publicado: (2010)

Search for the SM Higgs Boson in H->WW->lnu lnu with ATLAS
por: Schmidt, E
Publicado: (2012)

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
por: Lai, Gillianne G.Y., et al.
Publicado: (2022)

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
por: Sangro, Bruno, et al.
Publicado: (2020)

Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients
por: Chung, Min-Woo, et al.
Publicado: (2021)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021)

The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma
por: Kim, Han Sang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r091glkmvr3j4ujok92623t0oq